SCHEMBL375173

SCHEMBL375173

COc1cc(CN(C(=O)c2nc[nH]n2)C2CCOCC2)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 3/20 0.42
SLC6A5 Q9Y345 2/20 0.42
KCNH2 Q12809 2/20 0.41
REN P00797 3/20 0.40
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
MAPK1 P28482 1/20 0.38
CTSD P07339 2/20 0.38
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
CYP3A4 P08684 1/20 0.36
CHEK1 O14757 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375116 0.89 KDM4E (0.40) SLC6A9SLC6A5KCNH2ALDH1A1RAB9A
SCHEMBL374833 0.89 SLC6A9 (0.39) SLC6A9SLC6A5KCNH2RENCYP3A4
SCHEMBL375110 0.88 SLC6A9 (0.53) SLC6A9SLC6A5KCNH2RENLMNA
SCHEMBL375183 0.88 SLC6A9 (0.40) SLC6A9SLC6A5KCNH2RENCTSD
SCHEMBL375305 0.87 SLC6A9 (0.36) SLC6A9SLC6A5KCNH2ALDH1A1CYP3A4
SCHEMBL375006 0.83 PDE4D (0.39) SLC6A9SLC6A5KCNH2RENLMNA
SCHEMBL375594 0.82 KCNH2 (0.39) SLC6A9SLC6A5KCNH2KMT2ACYP3A4
SCHEMBL375432 0.81 EPHX1 (0.39) SLC6A9SLC6A5KCNH2CYP3A4
SCHEMBL375083 0.81 TACR1 (0.46) SLC6A9SLC6A5KCNH2LMNA
SCHEMBL375145 0.81 SLC6A4 (0.49) KCNH2LMNAMAPTTHRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 EP disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES SLC18A2, SLC1A2, SLC6A1 SLC6A9 8/4885SLC6A5 4/4885KCNH2 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.